AI基金摩根医疗健康股票A（001766）披露2025年二季报，第二季度基金利润3076.49万元，加权平均基金份额本期利润0.0838元。报告期内，基金净值增长 率为6.05%，截至二季度末，基金规模为5.25亿元。 该基金属于标准股票型基金，长期投资于医药医疗股票。截至7月21日，单位净值为1.623元。基金经理是叶敏，目前管理5只基金近一年均为正收益。其 中，截至7月18日，摩根中国生物医药混合(QDII)A近一年复权单位净值增长率最高，达56.52%；截至7月21日，摩根成长动力混合A最低，为15.32%。 基金管理人在二季报中表示，制药和器械是能够培育具有持续成长性的大市值公司的两个重要领域，我们也会不断自下而上发掘其中的投资机会。 截至7月21日，摩根医疗健康股票A近三个月复权单位净值增长率为15.94%，位于同类可比基金42/54；近半年复权单位净值增长率为30.20%，位于同类可比 基金34/54；近一年复权单位净值增长率为33.45%，位于同类可比基金30/53；近三年复权单位净值增长率为-19.12%，位于同类可比基金38/47。 通过所选区间该基金净值增长率分位图，可以观察该基金与同类基 ...

6年前，肩负着支持科技创新"前沿阵地"与改革"试验田"的重任，科创板掀开了中国资本市场注册制改 革的新篇，重塑资本服务实体经济的底层逻辑。 6年来，汇聚起589家"硬科技"企业的科创板从未停止探索与创新的步伐。一个月前，《关于在科创板设 置科创成长层 增强制度包容性适应性的意见》（以下简称《科创板意见》）发布，为服务科技创新和 新质生产力发展再度加码。 当前，新一轮科技革命和产业变革深入发展，面对科技型企业对资本市场提出的更加多样化需求，"以 在科创板设置专门层次为抓手，重启未盈利企业适用科创板第五套标准上市"，正是科创板给出的最新 答卷。 以集成电路为例，科创板集成电路上市公司达120家，涵盖芯片设计、制造、封测、设备、材料、软件 等产业链各环节，汇聚了中芯国际、中微公司、沪硅产业等主要行业龙头，逐步形成链条完整、协同创 新的发展格局，推动提升了我国集成电路产业的自主化水平。 与此同时，一批科创板公司持续推动前沿技术发展和产业变革，面向人工智能、基因技术、量子信息等 未来产业正加快布局。当前，我国科技领域，特别是在人工智能、商业航天、低空经济等领域取得较大 突破，更大力度支持这些行业企业发展、为投资者提供分 ...

Core Insights - The AI Fund Qianhai Kaiyuan Medical Health A (005453) reported a profit of 57.04 million yuan for Q2 2025, with a weighted average profit per fund share of 0.123 yuan. The fund's net value growth rate was 12.63%, and the fund size reached 498 million yuan by the end of Q2 2025 [2][15]. Fund Performance - As of July 18, 2025, the fund's one-year cumulative net value growth rate was 47.58%, ranking 52 out of 133 comparable funds. Over the past three months, the growth rate was 39.80%, ranking 25 out of 138 [3]. - The fund's three-year Sharpe ratio was -0.3238, ranking 99 out of 105 comparable funds [8]. - The maximum drawdown over the past three years was 51.82%, with the highest quarterly drawdown occurring in Q3 2021 at 27.66% [10]. Investment Strategy - The fund focuses on flexible allocation, primarily investing in pharmaceutical and healthcare stocks. In Q2 2025, it emphasized investments in high-growth biotech companies and traditional pharmaceutical firms entering a harvest phase for innovative drugs. The fund manager anticipates continued demand for innovative drugs from overseas pharmaceutical companies due to the overseas patent cliff, alongside a surge in domestic supply of innovative drugs [2]. - The fund aims to enhance its research on industry fundamentals and macro trends, employing both top-down and bottom-up analysis methods for sector allocation and individual stock valuation assessments [2]. Fund Holdings - As of Q2 2025, the top ten holdings of the fund included companies such as Sanofi Pharmaceutical, Diligent Pharma, Innovent Biologics, and BeiGene, among others [18]. Fund Positioning - The average stock position over the past three years was 90.14%, with a peak of 93.11% at the end of H1 2025 and a low of 65.37% at the end of H1 2019 [13].

Core Viewpoint - The AI Fund ICBC Healthcare Stock (000831) reported a profit of 209 million yuan for Q2 2025, with a weighted average profit per fund share of 0.1826 yuan, and a net asset value growth rate of 5.88% during the period [2]. Fund Performance - As of July 18, the fund's net asset value growth rates were 17.16% over three months, 28.87% over six months, 26.93% over one year, and -9.65% over three years, ranking 45/54, 38/54, 41/53, and 26/46 among comparable funds respectively [3]. - The fund's Sharpe ratio over the past three years was -0.0674, ranking 25/46 among comparable funds [9]. - The maximum drawdown over the past three years was 36.8%, with the largest single-quarter drawdown occurring in Q3 2022 at 24.01% [11]. Fund Composition and Strategy - As of June 30, the fund maintained an average stock position of 88.71% over the past three years, slightly above the comparable average of 88.19% [14]. - The top ten holdings of the fund as of Q2 2025 included companies such as Heng Rui Medicine, Kelun Pharmaceutical, and BeiGene, among others [19]. Market Outlook - The fund manager expressed optimism regarding long-term trends in refractive surgery technology, increasing penetration rates for myopia prevention, and growth in dental implants and medical aesthetics [2]. - The medical device sector is expected to face challenges in 2024, but a turning point may occur in the second half of 2025 as companies begin to alleviate inventory pressures [2].

华创医药团队重点看好的五大投资方向：一是创新药，看好优质滞涨及有明确低估、催化事件（如出 海、数据读出）的公司；二是创新产业链，随创新药发展将强劲增长；三是原料药，处于产业周期见 底、价格触底、产能利用率回升阶段；四是医疗设备，三季度多家公司同比环比增速回升，明年值得期 待；五是有竞争力的中药品种及转型创新药的中药品种。 医疗创新ETF 凭借紧密跟踪中证医药及医疗器械创新指数、低费率、高透明度及一键覆盖龙头的特 性，近3个月涨幅7.46%，近一年收益达18.38%，显著跑赢行业基准，是布局医药核心资产的利器。 展望未来，预计我国医疗卫生支出的总盘子仍将实现稳定的可持续增长。在行业稳步扩容下，寻找快于 行业平均增速的细分领域，将成为超额投资收益的核心来源，创新、消费升级、高端制造将是核心关键 词。长期来看，创新是医药行业永恒的主题、长期上行的驱动力，可借道医疗创新ETF(516820)把握优 质龙头错杀机会。 医疗创新ETF(516820)下跌1.08%，特宝生物(688278)领涨1.59%，惠泰医疗(688617)上涨1.04%，新产业 (300832)上涨0.24%；百利天恒(688506)领跌4.36% ...

Core Viewpoint - 加科思药业 has seen significant management confidence through recent share buybacks and purchases, indicating a belief in the undervaluation of the company and its pipeline potential [1][4] Group 1: Shareholder Actions - 加科思药业 announced that its concerted parties have recently increased their holdings by 854,400 shares at an average price of HKD 5.88 per share, totaling over HKD 5 million [1] - The company does not rule out the possibility of further share purchases in the future [1] - The management's high-level purchases reflect a strong belief in the company's value and pipeline confidence, especially after a 427% increase in stock price year-to-date [1] Group 2: Product Pipeline and Market Potential - The company's most notable product, the KRAS inhibitor JAB-23E73, has entered Phase I trials in China and the U.S., with a global sales peak potential of USD 12.1 billion, particularly in pancreatic and non-small cell lung cancers [2] - JAB-23E73 is a small molecule oral drug with promising pharmacokinetics and significant anti-tumor activity, showing a cost advantage over competitors [3] - 加科思's market capitalization is currently at HKD 5 billion, significantly lower than Revolution Medicine's USD 7 billion, indicating substantial upside potential [3] Group 3: Financial Outlook and Revenue Generation - The approval of the KRAS G12C inhibitor, 戈来雷塞, marks a critical milestone for 加科思, expected to generate stable cash flow through its commercialization [4] - 戈来雷塞 is priced at approximately HKD 38,000 per month, with a potential market size of HKD 6 billion based on patient demographics and market share estimates [4] - The strategic partnership with 艾力斯 for sales in China could yield approximately HKD 200 million annually from milestone and sales sharing, providing solid performance support for the company's current valuation [5] Group 4: Future Developments - The SHP2 inhibitor JAB-3312 is the first of its kind to enter Phase III trials, with potential implications for first-line treatment of non-small cell lung cancer, which could trigger additional milestones for 艾力斯 and become a new revenue source [6]

Investment Rating - The report maintains a "Recommended" investment rating for the pharmaceutical industry as of July 20, 2025 [1] Core Insights - The establishment of a positive innovation cycle is driving value enhancement in the pharmaceutical sector, particularly through overseas collaborations and the increasing recognition of the value of PD-1/VEGF dual antibodies [2] - The focus on tri-antibodies is rising, with significant potential for competition in first-line treatments, as evidenced by recent collaborations and promising clinical data [3] - The trend towards more effective and scientifically-backed weight loss solutions is evident, with GLP-1 drugs projected to generate over $50 billion in global sales in 2024, significantly boosting capital interest [5] - The trend in autoimmune drug development is shifting towards innovative therapies, with notable advancements in dual-target fusion proteins [6] - The approval of Vuxinib (伏欣奇拜单抗) marks a significant milestone in biological treatments for gout, with a substantial market potential due to the increasing prevalence of hyperuricemia and gout [7] Summary by Sections 1. Pharmaceutical Market Tracking - The pharmaceutical industry outperformed the CSI 300 index by 2.91 percentage points in the past week, with a weekly increase of 4.00%, ranking second among 31 primary industry indices [19] - Over the past month, the pharmaceutical sector outperformed the CSI 300 index by 5.90 percentage points, with an increase of 11.51%, ranking fourth among primary industry indices [21] 2. Pharmaceutical Sector Trends and Valuation - The pharmaceutical sector has shown a 14.50% increase over the past six months, outperforming the CSI 300 index by 4.46 percentage points [36] - The current PE (TTM) for the pharmaceutical sector is 37.25, which is above the five-year historical average of 32.24 [39] 3. Recent Research Achievements - The research team has published several in-depth reports highlighting the positive trends in supply and demand within the pharmaceutical industry, including the growth of blood products and the acceleration of the import substitution process in inhalation preparations [44] 4. Recent Industry Policies and News - Recent measures from the National Medical Insurance Administration aim to support the high-quality development of innovative drugs, enhancing their market access and clinical application [46] - Notable industry news includes the approval of new indications for existing drugs and significant collaborations between major pharmaceutical companies [47][49]

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Core Insights - The AI Fund Ping An Medical Health Mixed A (003032) reported a profit of 210 million yuan for Q2 2025, with a weighted average profit per fund share of 0.5108 yuan [2] - The fund's net value growth rate for the reporting period was 21.53%, and as of the end of Q2, the fund size was 966 million yuan [2] - The fund focuses on equity mixed investments, particularly in pharmaceutical and medical stocks, and has a current unit net value of 2.876 yuan as of July 17 [2] Performance Metrics - The fund manager highlighted a strategy based on the economic conditions of sub-industries, focusing on innovative drugs and medical devices as growth sectors [2] - As of July 17, the fund's one-year adjusted net value growth rate was 84.73%, ranking 5th out of 133 comparable funds [2] - The fund's three-month adjusted net value growth rate was 43.84%, ranking 9th out of 138 comparable funds [2] Risk and Volatility - The fund's three-year Sharpe ratio was 0.4698, ranking 15th out of 105 comparable funds [6] - The maximum drawdown over the past three years was 38.67%, with the largest single-quarter drawdown occurring in Q1 2024 at 30.45% [8] Investment Strategy - The fund maintained an average stock position of 90.2% over the past three years, compared to the industry average of 86.9% [11] - The fund's top ten holdings include companies such as CloudTop New Medicine, Innovent Biologics, and BeiGene, indicating a high concentration in its portfolio [15]

Group 1 - The core viewpoint of the articles emphasizes that the innovative drug sector in China is experiencing a transformation driven by international recognition, policy support, and market dynamics, leading to a potential revaluation cycle [1][5][9] - The total value of license-out transactions for Chinese innovative drugs exceeded $50 billion in 2023, with multiple drugs receiving FDA approval, indicating growing global market acceptance [1][5] - The Hong Kong stock market has become a preferred listing venue for Chinese innovative drug companies due to its international financing environment and flexible listing regulations, hosting numerous leading firms in cutting-edge fields such as oncology and gene therapy [1][5] Group 2 - The newly launched Hong Kong Stock Connect Innovative Drug ETF by Harvest Fund aims to provide investors with a one-click solution to invest in core assets of innovative drugs, tracking the CSI Hong Kong Stock Connect Innovative Drug Index [2][9] - The CSI Hong Kong Stock Connect Innovative Drug Index includes 50 companies involved in innovative drug research and development, with the top ten companies accounting for over 60% of the index's weight, showcasing significant representativeness [2][3] - As of July 15, 2025, the index has shown impressive performance, with a one-year increase of 109.13% and a year-to-date increase of 66.23%, outperforming similar indices and the broader market [4][5] Group 3 - The A-share Sci-Tech Innovation Board complements the Hong Kong market by attracting innovative drug companies with independent intellectual property, providing a financing channel for high-growth biotech firms [6][9] - The newly established Sci-Tech Medicine ETF by Harvest Fund tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedicine Index, covering various segments including innovative drugs and vaccines [6][9] - The combination of the Hong Kong and A-share markets creates a comprehensive investment strategy for Chinese innovative drugs, allowing investors to capture opportunities across the entire industry chain [9][10] Group 4 - The dual-market strategy of investing in both Hong Kong and A-share markets allows for a diversified approach, with the Hong Kong ETF focusing on mature innovative drug companies and the A-share ETF targeting early-stage firms with high growth potential [10][11] - This strategy aims to mitigate risks associated with market volatility while maximizing long-term investment value in the innovative drug sector [10][11] - Harvest Fund has developed a comprehensive ETF product line in the biopharmaceutical sector, including various thematic products to capture key industry opportunities [11]